Designing Effective Alcohol Health Warnings: An Experimental Study With Adults in the U.S.
8. september 2026 oppdatert av: University of Oklahoma
Consuming alcohol is a dose-dependent and modifiable risk factor for breast cancer.
Although alcohol consumption contributes to an estimated 16% of breast cancer cases, awareness of the link between alcohol and breast cancer risk remains low.
Systematically developed and tested health warnings can support population-based approaches and intervention strategies to decrease alcohol consumption and breast cancer risk.
For instance, the U.S. Food and Drug Administration can mandate specific warnings through statements (e.g., "WARNING: This product contains nicotine…") and color graphics depicting the negative health consequences of products that can harm public health, such as tobacco and alcohol.
However, health warning statements and graphics should be assessed among intended audiences before implementation.
Research has outlined principles for effective health warning statements.
This project will test different health warning statements about the health effects of alcohol.
Studieoversikt
Status
Rekruttering
Forhold
Detaljert beskrivelse
Health warning statements should be assessed for effectiveness among target audiences before implementation as interventions.
Research has outlined principles for effective health warning statements.
Specifically, health warning statements are effective when they impact mediators of health behavior (e.g., message perceptions, emotional/affective reactions, and resistance to messages) as well as actual behavior.
Guided by these assumptions, we will conduct an online randomized clinical trial (RCT) (N=2,000) with US female participants (ages 18 to 65 years) who report consuming alcohol in the past 30 days (i.e., people who currently drink) and young adult female non-drinkers (ages 18-29) to assess how both samples rate different alcohol health warning statements presented in different formats.
Studietype
Intervensjonell
Registrering (Antatt)
2000
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Zachary Massey, PhD
- Telefonnummer: (405) 271-6872
- E-post: zachary-massey@ou.edu
Studiesteder
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Rekruttering
- University of Oklahoma Health Campus, Health Promotion Research Center
-
Ta kontakt med:
- Zachary Massey, PhD
- Telefonnummer: 405-271-6872
- E-post: zachary-massey@ou.edu
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- being between 18 and 65 years of age
- assigned female at birth
- self-report having consumed alcohol in the last 30 days for the current drinker groups
- self-report not having consumed alcohol in the last 30 days for the nondrinker groups
- live in the US and able to read, speak, and understand English
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Faktoriell oppgave
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Health warning statement evaluations (bottles)
A randomized clinical trial (RCT) cohort of adult participants (18-65) will complete a computer-based survey-experiment during a single study visit (conducted online).
They will review a series of hypothetical alcohol products and rate the images.
|
The experiment will use a 2 (health warning statement: single-theme statement vs. composite paragraph) x 2 (pictogram: present vs. absent) x 2 (format: alcohol container vs. alcohol advertisement) between- and within-subjects design.
The between-subject groups are 2 (health warning statement: single-theme vs. composite message) x 2 (pictogram: present vs. absent), and the within-subjects factor is the format of warning presentation (2 alcohol containers vs. 2 alcohol advertisements).
|
|
Eksperimentell: Health warning statement evaluations (ads)
A randomized clinical trial (RCT) cohort of adult participants (18-65) will complete a computer-based survey-experiment during a single study visit (conducted online).
They will review a series of hypothetical alcohol products and rate the images.
|
The experiment will use a 2 (health warning statement: single-theme statement vs. composite paragraph) x 2 (pictogram: present vs. absent) x 2 (format: alcohol container vs. alcohol advertisement) between- and within-subjects design.
The between-subject groups are 2 (health warning statement: single-theme vs. composite message) x 2 (pictogram: present vs. absent), and the within-subjects factor is the format of warning presentation (2 alcohol containers vs. 2 alcohol advertisements).
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Risk perceptions of alcohol harms (questionnaire self-report)
Tidsramme: Assessed immediately after stimulus exposure.
|
Continuous self-report measure (1 to 9) for perceptions of severity and likelihood of negative health effects occurring as a result of alcohol consumption.
|
Assessed immediately after stimulus exposure.
|
|
Perceived efficacy to prevent alcohol harms (questionnaire self-report)
Tidsramme: Assessed immediately after stimulus exposure.
|
Continuous self-report measure (1 to 9) for perceptions of response and self-efficacy to protect against the negative health effects occurring as a result of alcohol consumption.
|
Assessed immediately after stimulus exposure.
|
|
Attitudes about alcohol consumption (questionnaire self-report)
Tidsramme: Assessed immediately after stimulus exposure.
|
Continuous self-report measure (1 to 7) for attitudes about alcohol consumption.
|
Assessed immediately after stimulus exposure.
|
|
Intentions to quit or reduce drinking alcohol (questionnaire self-report)
Tidsramme: Assessed immediately after stimulus exposure.
|
Continuous self-report measure (1 to 9) for intentions to quit or reduce alcohol consumption in the next 6 months.
|
Assessed immediately after stimulus exposure.
|
|
Intentions to seek information about alcohol health effects and cancer screenings (questionnaire self-report)
Tidsramme: Assessed immediately after stimulus exposure.
|
Continuous self-report measure (1 to 9) for intentions to seek information about the health effects of alcohol, including cancer screenings.
|
Assessed immediately after stimulus exposure.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Attention to warning statements (questionnaire self-report)
Tidsramme: Assessed immediately after stimulus exposure.
|
Continuous self-report measure (1 to 9) of attention to experimental images.
|
Assessed immediately after stimulus exposure.
|
|
Perceived message effectiveness (questionnaire self-report)
Tidsramme: Assessed immediately after stimulus exposure.
|
Continuous self-report measure (1 to 9) of perceived message effectiveness of health warnings in experimental images.
|
Assessed immediately after stimulus exposure.
|
|
Reactance (questionnaire self-report)
Tidsramme: Assessed immediately after stimulus exposure.
|
Continuous self-report measure (1 to 9) of opposition to the health warning information in experimental images.
|
Assessed immediately after stimulus exposure.
|
|
Emotional responses (questionnaire self-report)
Tidsramme: Assessed immediately after stimulus exposure.
|
Continuous self-report measure (1 to 9) for strength of positive to negative feeling/emotions about the experimental images.
|
Assessed immediately after stimulus exposure.
|
|
Alcohol product appeal (questionnaire self-report)
Tidsramme: Assessed immediately after stimulus exposure.
|
Continuous self-report measure (1 to 9) for appeal of products in experimental images.
|
Assessed immediately after stimulus exposure.
|
|
Unaided recall (i.e., correctly recalling health effects described in warnings)
Tidsramme: Assessed immediately after stimulus exposure.
|
Open-ended qualitative recall.
Participants are prompted to describe the health risks of alcohol use mentioned in the experimental images.
|
Assessed immediately after stimulus exposure.
|
|
"Masked" recall (i.e., viewing health warning stimuli with messages blurred to prompt recall of specific messages)
Tidsramme: Assessed immediately after stimulus exposure.
|
Participants view the 1st image they were exposed to in the experiment with the health warning blurred and are prompted to write down everything they can recall about it.
|
Assessed immediately after stimulus exposure.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
27. juli 2026
Primær fullføring (Antatt)
1. september 2026
Studiet fullført (Antatt)
1. september 2026
Datoer for studieregistrering
Først innsendt
27. august 2026
Først innsendt som oppfylte QC-kriteriene
8. september 2026
Først lagt ut (Faktiske)
10. september 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
10. september 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
8. september 2026
Sist bekreftet
1. september 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- 18774
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .